Edition:
United Kingdom

Conatus Pharmaceuticals Inc (CNAT.OQ)

CNAT.OQ on NASDAQ Stock Exchange Global Market

0.31USD
6:36pm BST
Change (% chg)

$-0.61 (-66.38%)
Prev Close
$0.92
Open
$0.35
Day's High
$0.39
Day's Low
$0.31
Volume
1,757,170
Avg. Vol
153,907
52-wk High
$6.73
52-wk Low
$0.31

Select another date:

Mon, Jun 24 2019

Conatus Pharma to explore options as liver disease drug fails trial

Conatus Pharmaceuticals Inc said on Monday it plans to explore options and implement a restructuring plan after its liver disease drug failed in a mid-stage trial.

UPDATE 1-Conatus Pharma to explore options as liver disease drug fails trial

June 24 Conatus Pharmaceuticals Inc said on Monday it plans to explore options and implement a restructuring plan after its liver disease drug failed in a mid-stage trial.

BRIEF-Conatus Says Top-Line Results From Encore-LF Clinical Trial Of Emricasan Did Not Meet Primary Endpoint

* CONATUS ANNOUNCES RESULTS FROM ENCORE-LF AND ENCORE-PH PHASE 2B CLINICAL TRIALS IN NASH CIRRHOSIS

Conatus Pharma to explore options, liver disease drug fails trial

June 24 Conatus Pharmaceuticals Inc said on Monday it will cut staff by about 40% as part of a restructuring plan and explore options.

BRIEF-Conatus Completes Enrollment In Phase 2B Clinical Trial Of Emricasan In Patients With Decompensated Nash Cirrhosis

* CONATUS ANNOUNCES COMPLETION OF ENROLLMENT IN ENCORE-LF PHASE 2B CLINICAL TRIAL OF EMRICASAN IN PATIENTS WITH DECOMPENSATED NASH CIRRHOSIS

Select another date: